GlassScriptPhysician profile
James Mauck
NPI 1467480996
$1,498.52
in general payments reported to CMS, 2019-2025
25 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $155 · 2021: $276 · 2022: $239 · 2023: $305 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $565 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $565.14 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $377.48 | 2019-2025 | |
| Astellas Pharma US INC | $157.80 | 2022-2025 | Veozah |
| Exact Sciences Corporation | $101.70 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $87.70 | 2019-2025 | |
| Coopersurgical, INC. | $82.06 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $71.33 | 2021-2025 | |
| Exeltis, USA INC. | $68.45 | 2021-2025 | Slynd |
| Therapeuticsmd, INC. | $62.37 | 2019-2022 | |
| Allergan, INC. | $57.75 | 2019-2020 | |
| Myovant Sciences INC. | $57.41 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.76 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $44.65 | 2023 | Myfembree |
| Ethicon US, LLC | $40.45 | 2019-2025 | Vistaseal, Ethicon |
| Hologic Sales and Service, LLC | $30.24 | 2020-2021 | |
| Kci USA, INC. | $29.35 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $25.59 | 2019-2020 | |
| Sanara Medtech INC. | $23.33 | 2021 | |
| Octapharma USA, INC. | $20.00 | 2025 | Fibryga |
| Biogen, INC. | $18.65 | 2025 | Zurzuvae |
| Aspira Women'S Health INC | $17.54 | 2025 | Ova1 |
| Organon LLC | $17.14 | 2021 | |
| Ardelyx, INC. | $16.00 | 2025 | Ibsrela |
| Shield Therapeutics INC | $13.86 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $12.94 | 2022 | |
| Merck Sharp & Dohme LLC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mauck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.